The old belief that testosterone therapy increases prostate cancer or makes it worse is no longer backed up by modern ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Nigeria records over 18,000 new prostate cancer cases annually, accounting for the highest cancer burden among men in the country.

Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...

Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

The Best SARMS for Strength, Cutting, Muscle Growth, Body Building & Recovery - A Guide to SARMs: Definition, Side Effects ...

Leuprorelin acetate, a medicine approved in the U.S. for prostate cancer, may slow the progression of SMA type SBMA, ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...